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Insulin stimulates glucose transport in adipocytes
and muscle cells by triggering redistribution of the
GLUT4 glucose transporter from an intracellular peri-
nuclear location to the cell surface. Recent reports have
shown that the microtubule-depolymerizing agent no-
codazole inhibits insulin-stimulated glucose transport,
implicating an important role for microtubules in this
process. In the present study we show that 2 M nocoda-
zole completely depolymerized microtubules in 3T3-L1
adipocytes, as determined morphologically and bio-
chemically, resulting in dispersal of the perinuclear
GLUT4 compartment and the Golgi apparatus. However,
2 M nocodazole did not significantly effect either the
kinetics or magnitude of insulin-stimulated glucose
transport. Consistent with previous studies, higher con-
centrations of nocodazole (10–33 M) significantly inhib-
ited basal and insulin-stimulated glucose uptake in adi-
pocytes. This effect was not likely the result of
microtubule depolymerization because in the presence
of taxol, which blocked nocodazole-induced depolymer-
ization of microtubules as well as the dispersal of the
perinuclear GLUT4 compartment, the inhibitory effect
of 10–33 M nocodazole on insulin-stimulated glucose
uptake prevailed. Despite the decrease in insulin-stim-
ulated glucose transport with 33 M nocodazole we did
not observe inhibition of insulin-stimulated GLUT4
translocation to the cell surface under these conditions.
Consistent with a direct effect of nocodazole on glucose
transporter function we observed a rapid inhibitory ef-
fect of nocodazole on glucose transport activity when
added to either 3T3-L1 adipocytes or to Chinese hamster
ovary cells at 4 °C. These studies reveal a new and un-
expected effect of nocodazole in mammalian cells which
appears to occur independently of its microtubule-depo-
lymerizing effects.
Insulin stimulates glucose transport in muscle and fat cells
by regulated vesicular transport (1–4). In the absence of insu-
lin GLUT4, the major glucose transporter isoform expressed in
these cells, is stored in an intracellular tubulovesicular com-
partment. Insulin stimulates the exocytosis of GLUT4 from
this compartment, leading to increased GLUT4 levels at the
cell surface. This process occurs with a t1/2 of 2–5 min.
Several recent studies have suggested an important role for
microtubules in insulin-regulated GLUT4 trafficking. First,
tubulin- and vimentin have been identified as major compo-
nents of intracellular GLUT4 vesicles in adipocytes (5). Second,
it has been shown that insulin stimulates the long range move-
ment of GLUT4 vesicles along linear tracks in adipocytes (6).
Third, the microtubule-depolymerizing drug nocodazole inhib-
ited insulin-stimulated glucose transport in adipocytes (7, 8).
Finally, nocodazole caused a dispersal of the perinuclear
GLUT4 compartment in adipocytes (7, 9). These studies have
led to the notion that microtubules may play a fundamental
role in GLUT4 trafficking and insulin action. It has been pro-
posed that insulin may stimulate GLUT4 exocytosis, at least in
part, by increasing the rate of association of GLUT4-containing
membranes with microtubules. This step likely occurs in the
perinuclear region of the cell, implicating an important role for
the perinuclear localization of GLUT4 in insulin action (5, 7).
In the present studies we have examined the dose response
effects of nocodazole on microtubule integrity and insulin ac-
tion in 3T3-L1 adipocytes. Using morphological and biochemi-
cal methods we observed maximal effects of nocodazole on
microtubule depolymerization at a concentration of 2 M. Func-
tional consequences of microtubule depolymerization were ob-
served at 2 M nocodazole in that the Golgi apparatus and the
perinuclear GLUT4 compartment were dispersed throughout
the cytoplasm of the cell. Despite these effects there was no
significant inhibition of insulin-stimulated glucose transport or
GLUT4 translocation at 2 M nocodazole. At higher nocodazole
concentrations (10–33 M) we observed inhibition of glucose
transport consistent with previous studies (7, 8). We present
data to show that the inhibitory effects of high concentrations
of nocodazole are the result of an inhibitory effect of the drug on
glucose transport activity rather than on the insulin-dependent
recruitment of GLUT4 to the cell surface. We conclude that
nocodazole does not inhibit insulin-stimulated GLUT4 translo-
cation in 3T3-L1 adipocytes.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—All tissue culture media were purchased
from Life Technologies, Inc., except fetal calf serum, which was ob-
tained from Trace Biosciences (Clayton, Australia). Insulin, nocodazole,
and taxol were obtained from Calbiochem. Bicinchoninic acid reagent,
used in protein assays, and ECL Supersignal reagent were obtained
from Pierce (Rockford, IL). BSA1 was purchased from ICN (Costa Mesa,
CA). Polyvinylidene difluoride blotting membranes were obtained from
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Millipore Corp. (Beldford, MA). Unless specified, all other reagents
were from Sigma. The GLUT4 polyclonal antibody (R017) was raised
against a synthetic peptide corresponding to the COOH-terminal 20
amino acids of rat GLUT4. Monoclonal vimentin antibody, V9.5, was a
gift from Dr. Robert M. Evans (Department of Pathology, University of
Colorado, Denver). Monoclonal anti-tubulin- antibody (DM1A) was
from Sigma, and monoclonal anti-HA (16B12) was purchased from
BabCO (Richmond, CA). Phalloidin-fluorescein isothiocyanate and all of
the fluorophore-tagged secondary antibodies were obtained from Molec-
ular Probes (Eugene, OR). Peroxidase-coupled secondary antibodies
were purchased from Amersham Pharmacia Biotech Inc. (Little
Chafton, U. K.).
Cell Culture and Transfection—3T3-L1 fibroblasts obtained from the
American Type Culture Collection (Rockville, MD) were cultured and
differentiated into adipocytes as described previously (10). Chinese
hamster ovary (CHO) cells were cultured as described previously (11).
116 (HA-GLUT4) 3T3-L1 adipocytes were obtained by transfection of
3T3-L1 fibroblasts with the retroviral expression vector pBabepuro
containing GLUT4 HA-tagged at the extracellular loop, as described by
Shewan et al. (12). Briefly, cells were infected with the relevant virus
for 3–5 h in the presence of 4 g/ml Polybrene (Sigma). After a 48-h
recovery period, infected cells were selected in Dulbecco’s modified
Eagle’s medium containing 5% fetal calf serum supplemented with 2
g/ml puromycin (Sigma) and then differentiated as described above.
Glucose Uptake Assays—Cells cultured in 6- or 12-well plates were
serum starved in KRP buffer (25 mM HEPES, pH 7.4, 120 mM NaCl, 6
mM KCl, 1.2 mM Mg SO4, 1 mM CaCl2, 0.4 mM NaH2PO4, 0.6 mM
Na2HPO4) containing 0.2% bovine serum albumin for 2 h at 37 °C. Cells
were incubated in 950 l of KRP buffer with the corresponding agents
at the times and doses indicated in the figure legends. 2-Deoxy-[3H]glu-
cose (2-DOG) uptake was measured as described previously (13).
Briefly, the assay was initiated by the addition of 50 l of 1 mM 2-DOG
(20 Ci/mmol). After 4 min, the assay was terminated by washing the
cells rapidly three times with ice-cold PBS. Cells were subsequently
solubilized in 1% Triton X-100, and 3H was quantified by scintillation
counting (Packard 1900CA liquid scintillation analyzer, Packard In-
strument Co.). Nonspecific 2-DOG uptake was determined in the pres-
ence of 50 M cytochalasin B.
Indirect Immunofluorescence Microscopy—Cells cultured on cover-
slips in 6- or 12-well dishes were starved for 2 h in Dulbecco’s modified
Eagle’s medium containing 0.2% BSA or in KRP buffer containing 0.2%
BSA buffer and incubated with the appropriate treatments. Cells were
fixed with acetone for 5 min, washed with PBS, washed again with PBS
containing 0.15 M in glycine, and incubated with 1% BSA containing
PBS for 30 min. Cells were incubated with primary antibodies and
diluted in PBS containing 1% BSA for 1 h. Cells were then washed with
PBS containing 0.1% BSA and incubated for 30 min with phalloidin-
fluorescein isothiocyanate or with the corresponding Alexa 488- or
Alexa 594-conjugated secondary antibody diluted in PBS containing 1%
BSA. Normal rabbit serum was used as a negative control. Coverslips
were washed with PBS, mounted onto glass microscope slides, and
viewed using an X63/1.4 Zeiss oil immersion objective on a Zeiss Axio-
vert fluorescence microscope, equipped with a Bio-Rad MRC-600 laser
confocal imaging system. In experiments designed for staining of cy-
toskeletal structures, cells were fixed and permeabilized simulta-
neously in cytoskeleton-stabilizing buffer (10 mM PIPES, pH 6.9, 100
mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA) as described by
Arcangeletti et al. (14).
The preparation of plasma membrane (PM) lawns was performed as
described by Robinson et al. (15). Briefly, after incubating cells on
coverslips with the appropriate treatment, adipocytes were sonicated
yielding a lawn of PM fragments attached to the coverslip. Coverslips
were then incubated with the relevant antibodies followed by Alexa
594-conjugated secondary antibody. The fluorescence intensity of indi-
vidual PM fragments (100–200) from five random fields for each exper-
imental condition was quantified using NIH 1.62 software. The assay
and quantitation were performed by separate investigators in a double
blind fashion. In addition, parallel experiments measuring tubulin de-
polymerization and glucose transport were performed.
In experiments designed for cell surface staining, 3T3-L1 adipocytes
expressing HA-tagged GLUT4 (12) were fixed in 2% paraformaldehyde
in PBS for 20 min but not permeabilized. Cells were incubated with the
anti-HA antibody for 1 h, washed, and incubated with the correspond-
ing Alexa 488-conjugated secondary antibody, as described above, and
visualized using an X63/1.4 Zeiss oil immersion objective on a Zeiss
Axiovert fluorescence microscope, equipped with a Bio-Rad MRC-600
laser confocal imaging system. In some cases we also quantified surface
labeling using a colorimetric detection assay as previously described
(16). Briefly, adipocytes expressing HA-GLUT4 were grown in 24-well
plates. Following the appropriate treatment cells were washed twice in
PBS and fixed in 2% paraformaldehyde in PBS for 5 min. Cells were
incubated with 2.5% normal swine serum and PBS for 30 min then
incubated with anti-HA antibody in 1% normal swine serum in PBS or
in 1% normal swine serum in PBS alone as a control for 60 min. After
washing in 0.1% BSA in PBS (3  10 min) cells were incubated with
anti-mouse:horseradish peroxidase conjugate (1:5,000) in 2.5% normal
rat serum in PBS for 30 min. Cells were then washed three times for 10
min each in PBS followed by incubation in o-phenylenediamine dihy-
drochloride reagent, made up according to the manufacturer’s instruc-
tions (Sigma) for 30 min in the dark. The absorbance of the supernatant
was measured at 450 nM.
Extraction of Polymerized Tubulin and Western Blotting—Polymer-
ized tubulin was extracted from 3T3-L1 adipocytes cultured on 10-cm
dishes as described previously (17). Briefly, cells were serum starved for
2 h by incubation in the presence of KRP buffer containing 0.2% BSA
prior to different treatments. At the conclusion of the treatment period,
cells were washed with PBS and incubated with 1 ml of Triton X-100
extraction buffer (2 M glycerol, 0.1 M PIPES, pH 7.1, 1 mM MgSO4, 1 mM
EGTA, 0.1% Triton X-100, 10 g/ml aprotinin, 10 g/ml leupeptin, 0.25
mM phenylmethylsulfonyl fluoride) for 30 min at 37 °C. The superna-
tant, containing the nonpolymerized tubulin, was discarded. One ml of
SDS buffer (25 mM Tris-HCl, pH 7.4, 0.4 M NaCl, 0.5% SDS) was added
to the dish for 5 min at 37 °C to solubilize the remaining Triton X-100-
insoluble protein containing polymerized tubulin. 20-g aliquots of the
Triton X-100-insoluble protein was resolved by SDS-polyacrylamide gel
electrophoresis (18) and transferred overnight to polyvinylidene diflu-
oride membranes. Membranes were immunoblotted using a specific
anti-tubulin monoclonal antibody (DM1A) followed by incubation with
horseradish peroxidase-conjugated goat anti-mouse secondary anti-
body. Immunoreactive bands were visualized by enhanced chemilumi-
nescence using Supersignal reagent. Autoradiograms were quantified
using a model GS-670 imaging densitometer (Bio-Rad).
Statistical Analysis—Statistical analyses were performed using
Sigma Plot software. Statistical significance was established by Stu-
dent’s t test (p  0.05).
RESULTS
Microtubule Integrity Is Not Required for Insulin-stimulated
Glucose Transport—Treatment of adipocytes with 0.2 M no-
codazole for 1 h decreased the amount of polymerized tubulin
by 65%, and a maximal effect of nocodazole (95% depolymer-
ization) was observed at a nocodazole concentration of 2 M
(Fig. 1). Time course experiments revealed that these effects
were rapid, occurring within 15 min of treatment (data not
FIG. 1. Microtubule integrity is not required for insulin-stim-
ulated glucose transport. 3T3-L1 adipocytes were brought to basal
conditions in KRP buffer containing 0.2% BSA buffer and then incu-
bated with dimethyl sulfoxide or nocodazole at the indicated concentra-
tion for 1 h. Cells were then incubated in the absence (filled circles) or
presence (open circles) of 100 nM insulin for the last 15 min. 2-DOG
uptake assays were performed as described under “Experimental Pro-
cedures.” Error bars correspond to the S.E. from three independent
experiments. *, p  0.01 compared with 2 M nocodazole. Polymerized
tubulin was extracted and visualized by Western blotting as described
under “Experimental Procedures” (filled triangles). Error bars corre-
spond to the S.E. from three independent experiments. , p  0.03
compared with 0.2 M nocodazole.
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shown). Even though we observed a maximal effect of nocoda-
zole on microtubule depolymerization at a concentration of 2
M we observed no significant inhibition of insulin-stimulated
glucose transport or GLUT4 translocation under the same ex-
perimental conditions. Studies examining the effects of nocoda-
zole on microtubules frequently use this drug at concentrations
10 M. At a concentration of 33 M, nocodazole caused an 80%
decrease in insulin-stimulated 2-DOG uptake (Fig. 1), consist-
ent with previous reports (7, 8). Basal 2-DOG uptake was also
inhibited significantly in the presence of 33 M nocodazole
(75%). Basal and insulin-stimulated glucose transport were
completely restored after removal of nocodazole from the cul-
ture medium (data not shown), ruling out possible cytotoxic
effects of the drug.
To confirm the dose response effects of nocodazole on the
integrity of microtubules in 3T3-L1 adipocytes we performed
immunofluorescence microscopy on 3T3-L1 adipocytes using an
anti-tubulin antibody. In the absence of nocodazole we ob-
served an elaborate microtubule network in adipocytes. Micro-
tubules radiated from the microtubule-organizing center to the
cell periphery where they formed a tight cortical network (Fig.
2a). After incubation of adipocytes with 2 M nocodazole micro-
tubules were completely absent (Fig. 2b), corroborating the
biochemical data (Fig. 1). Treatment with 2 M nocodazole also
promoted reorganization of vimentin-containing intermediate
filaments into thick bundles localized beneath the PM and
encapsulating the lipid droplets (Fig. 2, c versus d). The actin-
based microfilaments, which presented as a cortical rim under-
lying the PM, were unaffected by nocodazole treatment (Fig. 2,
e and f). Comparable results were achieved when cells were
incubated with higher concentrations (10–33 M) of nocodazole
(data not shown).
Dispersal of the Perinuclear GLUT4 Compartment Does Not
Inhibit Insulin-stimulated Translocation—We next examined
the effects of 2 M nocodazole on the localization of GLUT4 in
basal and insulin-stimulated adipocytes using indirect immu-
nofluorescence microscopy. Insulin induced the translocation of
GLUT4 from a perinuclear location to the cell surface (Fig. 3,
basal versus ins). Treatment with 2 M nocodazole resulted in
complete dispersal of the GLUT4 perinuclear compartment
throughout the cytoplasm (Fig. 3, basal versus noc). Nocodazole
(2 M) had no apparent effect on insulin-stimulated transloca-
tion of GLUT4 to the PM (Fig. 3, ins versus nocins), consistent
with the glucose transport data presented above (Fig. 1). These
data suggest that an intact GLUT4 perinuclear compartment is
not required for efficient insulin-stimulated GLUT4 transloca-
tion. One possibility that has been proposed (7) is that micro-
tubules regulate the movement of GLUT4 from its perinuclear
compartment to the cell cortex whereupon they may be es-
corted to the surface membrane by actin filaments. Microtu-
bule depolymerization may therefore affect the kinetics but not
the magnitude of GLUT4 delivery to the cell surface. Extensive
time course experiments were performed to look at both
GLUT4 translocation and glucose transport in the presence of
2 M nocodazole. As shown in Fig. 4, we were unable to observe
any significant change in the kinetics of either insulin-stimu-
lated glucose transport or GLUT4 translocation to the PM in
response to nocodazole.
Taxol Does Not Rescue the Inhibition of Insulin-stimulated
Glucose Transport Induced by High Doses of Nocodazole—One
possibility to explain the dose response effects of nocodazole on
glucose transport (Fig. 1) is that at high doses nocodazole may
FIG. 2. Effect of nocodazole on the cytoskeleton in 3T3-L1 adi-
pocytes. 3T3-L1 adipocytes cultured on coverslips were brought to
basal conditions and then incubated for 1 h with dimethyl sulfoxide (a,
c, and e), or 2 M nocodazole (b, d, and f). Cells were fixed and perme-
abilized in 2% paraformaldehyde/0.2% Triton X-100 in cytoskeleton-
stabilizing buffer, and cytoskeletal elements were visualized by indirect
immunofluorescence using anti-tubulin antibodies (a and b), anti-vi-
mentin antibodies (c and d), or phalloidin-fluorescein isothiocyanate (e
and f) as described under “Experimental Procedures.” Bar, 25 m.
FIG. 3. The perinuclear location of GLUT4 is not required for
insulin-stimulated GLUT4 translocation. 3T3-L1 adipocytes cul-
tured onto coverslips were brought to basal conditions in KRP buffer
containing 0.2% BSA buffer and then incubated in dimethyl sulfoxide
(basal) or 2 M nocodazole (noc) for 1 h. Where indicated, 100 nM insulin
(ins) was added for the last 15 min. Cells were then fixed in acetone, and
GLUT4 labeling was visualized by indirect immunofluorescence as de-
scribed under “Experimental Procedures.”
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inhibit insulin-stimulated glucose transport via a microtubule-
independent effect. To test this hypothesis we employed the
anti-tumor agent taxol, which stabilizes microtubules (19). We
reasoned that taxol may prevent any effects of nocodazole aris-
ing from microtubule depolymerization but not indirect effects
of the drug. Treatment of adipocytes with 40 M taxol for 1 h
promoted an increase in the level of polymerized tubulin (Fig.
5A). Moreover, taxol completely prevented the depolymeriza-
tion of microtubules observed following incubation of cells with
33 M nocodazole. The presence of an intact microtubule net-
work in cells treated simultaneously with 33 M nocodazole and
40 M taxol was confirmed by indirect immunofluorescence
microscopy (data not shown). To confirm that taxol restored the
function of the microtubule network we examined the localiza-
tion of GLUT4 as well as two Golgi markers, syntaxin 6 and
GS-15. As indicated in Fig. 5B, taxol completely prevented the
nocodazole-induced redistribution of GLUT4 from its perinu-
clear location. Similar results were obtained for both syntaxin
6, a trans-Golgi network marker (20), and GS-15, a protein
present in the Golgi apparatus (21) (data not shown).
We next examined the effects of taxol on 2-DOG uptake in
adipocytes. Taxol alone had no significant effect on either basal
or insulin-stimulated 2-DOG uptake (Fig. 5C) or GLUT4 trans-
location (data not shown). However, taxol was unable to over-
come the inhibitory effect of 33 M nocodazole on basal or
insulin-stimulated 2-DOG uptake (Fig. 5C).
Nocodazole Inhibits Glucose Transport Activity Independ-
ently of Effects on Signaling or Trafficking—Even though 33
M nocodazole inhibited insulin-stimulated glucose transport
by 80%, we were unable to detect any significant decrease in
insulin-stimulated GLUT4 translocation in the presence of
high doses of nocodazole, as measured by the PM lawn assay
(Fig. 6, A and B). Moreover, the movement of GLUT4 to the cell
surface in the presence of 33 M nocodazole resulted in its
productive fusion with the PM (Fig. 6, C and D), as determined
by surface labeling of a GLUT4 construct bearing an HA
epitope in one of its exofacial domains (22).
The most likely explanation for these data is that nocodazole
somehow impairs the transport properties of GLUT4 after it
has fused with the PM. To test this hypothesis we performed
two separate experiments. First, we examined the reversal of
nocodazole treatment on glucose transport under conditions in
which membrane trafficking was inhibited (i.e. at 4 °C). Cells
were pretreated with 33 M nocodazole for 1 h, and insulin was
added during the last 15 min. The cells were cooled rapidly to
4 °C to immobilize GLUT4 at the cell surface, by washing with
ice-cold KRP/BSA buffer in the presence or absence of 33 M
nocodazole. After a 5-min incubation at 4 °C, 2-DOG uptake
was measured. As shown in Fig. 7A, when 2-DOG uptake was
measured at 4 °C the stimulatory effect of insulin was main-
tained. Similarly, the inhibitory effects of 33 M nocodazole on
glucose transport were also maintained when 2-DOG assays
were performed at 4 °C. In contrast, when nocodazole was
withdrawn during the 5-min incubation at 4 °C there was a
dramatic reversal in insulin-dependent glucose transport ap-
proaching values observed in control cells. These data provide
further evidence that nocodazole does not interfere with traf-
ficking of GLUT4 but somehow impairs the activity properties
of the transporter itself. The second experiment that we per-
formed was to determine whether nocodazole could inhibit
glucose transport after the translocation process was complete.
3T3-L1 adipocytes were stimulated with insulin for 15 min at
37 °C to promote translocation of GLUT4 to the cell surface.
Cells were then cooled rapidly to 4 °C, to prevent further traf-
ficking, and then incubated with nocodazole on ice for 30 min
prior to measurement of 2-DOG uptake, which was also per-
formed at 4 °C. The low dose of nocodazole (2 M) had no
significant effect on glucose transport when added at 4 °C,
whereas the high dose of nocodazole (33 M) resulted in 80%
inhibition of insulin-stimulated 2-DOG uptake (Fig. 7B). Sim-
ilar effects of 33 M nocodazole were also observed after a 2-min
incubation with the drug at 4 °C, suggesting that this inhibi-
tory effect was rapid (data not shown). As a control for these
experiments we also examined the effects of the phosphatidyl-
inositol 3-kinase inhibitor, wortmannin, at 4 °C. Although this
drug inhibits insulin-stimulated glucose transport when added
prior to insulin treatment at 37 °C we observed no inhibitory
FIG. 4. Nocodazole does not affect
the kinetics of insulin-stimulated
glucose transport or GLUT4 translo-
cation. 3T3-L1 adipocytes were brought
to basal conditions in KRP buffer contain-
ing 0.2% BSA buffer and then incubated
in the absence (filled circles) or presence
(open circles) of 2 M nocodazole (noc) for
1 h. 100 nM insulin (ins) was added for
various periods of time as indicated after
which either 2-DOG uptake (A) or GLUT4
translocation (B and C) was measured.
2-DOG uptake was measured at 4 °C to
avoid changes in GLUT4 translocation
during the actual transport assay.
GLUT4 translocation was measured us-
ing the PM lawn assay as described under
“Experimental Procedures.” In B repre-
sentative fields of PM lawns from differ-
ent time points are shown. Fluorescence
associated with individual PM fragments
was quantified (C). Data shown are the
mean  S.E. of three separate
experiments.
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effect on insulin action when it was added after insulin at 4 °C
(Fig. 7B).
To determine whether the inhibition of glucose transport by
nocodazole was specific to GLUT4 or common to other facilita-
tive glucose transporters we examined the effects of nocodazole
on glucose uptake in CHO cells, which only express the GLUT1
isoform (23). Treatment of CHO cells with 33 M nocodazole
at  4 °C inhibited 2-DOG uptake by 60% (Fig. 7C). These data
indicate that nocodazole inhibits glucose uptake by both
GLUT4 and GLUT1 transporters in a rapid, dose-dependent
manner, which is independent of effects on signaling or
trafficking.
DISCUSSION
Nocodazole is frequently used by cell biologists to examine
the role of microtubules in vesicle transport. Although causing
complete fragmentation of the Golgi apparatus, nocodazole has
limited effects on vesicle transport between the Golgi and the
FIG. 5. Taxol does not rescue the inhibition of glucose trans-
port by nocodazole. 3T3-L1 adipocytes were brought to basal condi-
tions in KRP buffer containing 0.2% BSA buffer and then incubated in
the absence (B, basal) or presence of 33 M nocodazole (N, noc) and/or
40 M taxol (T, tax) for 1 h. A, polymerized tubulin was extracted as
described under “Experimental Procedures” and visualized by Western
blot using anti-tubulin- antibodies. A representative blot of three
separate experiments is shown. B, cells cultured on coverslips were
treated with nocodazole and/or taxol as described above. Cells were
fixed in acetone, and GLUT4 labeling was visualized by indirect immu-
nofluorescence as described under “Experimental Procedures.” C, cells
were treated with nocodazole and/or taxol as described above, and
where indicated, 100 nM insulin was added for the last 15 min. 2-DOG
uptake assays were performed as described under “Experimental Pro-
cedures.” Error bars correspond to the S.E. from three independent
experiments. * indicates the absence versus presence of nocodazole in
insulin-stimulated cells, p  0.00002.
FIG. 6. Nocodazole does not inhibit GLUT4 translocation to
the cell surface. A and B, 3T3-L1 adipocytes were grown on glass
coverslips and brought to basal conditions in KRP buffer containing
0.2% BSA buffer and then incubated in the absence (con) or presence of
either 2 M or 33 M nocodazole (noc) for 1 h at 37 °C. 100 nM insulin
(ins) was added during the last 15 min, and the PM lawn assay was
performed as described. Representative fields of PM lawns from differ-
ent treatment groups (A) and quantitation of five different experiments
(B) are shown. C and D, 3T3-L1 adipocytes expressing an HA-tagged
GLUT4 molecule were incubated as described above. At the conclusion
of the experiment cells were fixed, and cell surface-expressed GLUT4
was determined by labeling with an HA monoclonal antibody (panel C).
Representative fields of surface labeled cells from two separate exper-
iments are shown. D, quantitation of surface HA-GLUT4 labeling was
performed by a colorimetric assay as described under “Experimental
Procedures.” Error bars correspond to the S.E. from three independent
experiments.
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cell surface and on endosomal recycling. Nocodazole has little
effect on recycling of the transferrin receptor (24), membrane
protein processing in the Golgi (25), or retrieval of membrane
proteins from the early endosome back to the trans-Golgi net-
work (26). On the other hand, nocodazole perturbs membrane
traffic between early endosomes and lysosomes (26, 27). Simi-
lar results have been observed using alternate strategies to
disrupt microtubule function. For example, overexpression of
dynamitin mutants, which disrupt the function of microtubule
motors, also perturbs trafficking to the lysosome, whereas en-
dosomal recycling is unaffected (27). Several recent studies
have reported that nocodazole inhibits insulin-stimulated glu-
cose transport in adipocytes (7, 8). This is of interest because it
has been suggested that intracellular GLUT4-containing vesi-
cles may represent specialized recycling vesicles (1). Hence,
these effects may be consistent with a unique mode of transport
for GLUT4 to the cell surface compared with other recycling
proteins such as the transferrin receptor.
In the present study we have examined the effects of nocoda-
zole on GLUT4 trafficking and glucose transport in detail.
Initially, we studied the dose response effects of nocodazole on
microtubule depolymerization and observed maximal effects of
the drug at a concentration of 2 M. At this concentration of
nocodazole we observed marked fragmentation of the Golgi
apparatus and the perinuclear GLUT4 compartment. Despite
these effects, the ability of insulin to stimulate GLUT4 trans-
location and glucose transport was unaffected by nocodazole.
Hence, these data suggest that maintenance of the perinuclear
GLUT4 compartment is not essential for insulin-mediated traf-
fic to the cell surface (5–9). These observations are perhaps not
surprising because this perinuclear compartment of GLUT4
may not represent the major insulin responsive pool (28). Pre-
vious immunoelectron micrographic studies in 3T3-L1 adipo-
cytes indicate that GLUT4 is distributed between the trans-
Golgi network and small tubulovesicular elements scattered
throughout the cytoplasm (28). The trans-Golgi network pool,
which likely constitutes the perinuclear labeling typically ob-
served in 3T3-L1 adipocytes by immunofluorescence micros-
copy, does not represent the major intracellular insulin-respon-
sive compartment. Although depolymerization of microtubules
may not effect the magnitude of the GLUT4 translocation, it is
possible that nocodazole may slow the rate of movement of
these vesicles to the cell surface, as proposed previously (9). To
investigate this possibility we studied the kinetics of GLUT4
translocation and glucose transport in the presence of nocoda-
zole. However, we could find no evidence to indicate that the
kinetics of GLUT4 translocation or glucose transport activation
by insulin was impeded in the presence of nocodazole.
The observation that nocodazole had no effect on insulin-
stimulated glucose transport was surprising in light of previous
studies (7, 8). However, in each of these previous studies con-
centrations of nocodazole in excess of 10 M were used to study
effects on glucose transport. Consistent with these previous
studies, we observed a dose-dependent inhibition of nocodazole
on insulin-stimulated glucose transport (Fig. 1). At 33 M no-
codazole we observed 80% inhibition of insulin-stimulated
glucose transport. This effect was not likely to be the result of
depolymerization of microtubules because at high doses of no-
codazole we were able to reverse the microtubule- depolymer-
izing effects with taxol but not the inhibition of glucose trans-
port (Fig. 5). Strikingly, although nocodazole had a pronounced
inhibitory effect on insulin-stimulated glucose transport we
were unable to detect any inhibitory effect on GLUT4 translo-
cation to the cell surface (Fig. 6). This was not due to an effect
of nocodazole on fusion of the GLUT4 vesicles with the PM
because we also observed normal GLUT4 translocation using a
surface binding assay that only measures transporters that
have been incorporated into the PM (Fig. 6, C and D). These
results contrast with two other reports in which nocodazole was
shown to inhibit GLUT4 translocation, as determined by the
PM lawn assay (8, 9). The basis for this discrepancy is not clear.
FIG. 7. Nocodazole inhibits glucose transporter activity in
both 3T3-L1 adipocytes and CHO cells. A, 3T3-L1 adipocytes were
incubated with 33 M nocodazole (noc) for 1 h at 37 °C. 100 nM insulin
(ins, open bars) was added during the last 15 min of the incubation.
Cells were cooled rapidly by washing with KRP buffer (/nocodazole)
preequilibrated to 4 °C and incubated in the same buffer (/nocoda-
zole) for 5 min at 4 °C. 2-DOG uptake measurements were performed at
4 °C. Data shown represent the mean  S.D. of two experiments. B,
3T3-L1 adipocytes were brought to basal conditions in KRP buffer
containing 0.2% BSA buffer and then incubated in the absence (basal)
or presence of 100 nM insulin (ins) for 15 min. Where indicated, cells
were incubated with 100 nM wortmannin 10 min prior to insulin treat-
ment (wins). Cells were then rapidly cooled to  4 °C by washing in
ice-cold buffer and incubated at  4 °C in buffer with 100 nM wortman-
nin (inswort), 2 M nocodazole (ins  2 M noc), or 33 M nocodazole
(ins 33 M noc) for 30 min. 2-DOG uptake was measured for 90 s as
described under “Experimental Procedures.” Error bars correspond to
the S.D. from two separate experiments. C, CHO cells, grown in 12-well
plates, were cooled rapidly to  4 °C and incubated with 33 M nocoda-
zole for the indicated times. 2-DOG uptake was measured for 90 s as
described under “Experimental Procedures.” Error bars correspond to
the S.D. from two separate experiments.
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In the present study we have used three different approaches
to determine the extent of GLUT4 translocation to the cell
surface, and all three methods indicate that nocodazole at
either low or high doses does not inhibit this process signifi-
cantly. In parallel, we observed a dramatic effect of nocodazole
on the integrity of microtubules and the perinuclear GLUT4
compartment as well as on cellular glucose transport. Hence, it
is unlikely that nocodazole was inactive in our assay systems.
The observation that nocodazole inhibited glucose transport
independently of translocation of GLUT4 to the cell surface
argues strongly in favor of a direct effect of this drug on the
transport activity of the protein. In support of this hypothesis
we observed that nocodazole inhibited glucose transport in
adipocytes even when it was added to cells at 4 °C (Fig. 7B).
Under these conditions activation of glucose transport does not
rely upon vesicle transport or signal transduction. Further-
more, similar effects were observed in cells that do not express
the GLUT4 transporter (Fig. 7C). Moreover, these inhibitory
effects were rapid (Fig. 7C). The precise nature of this inhibi-
tory effect of nocodazole remains to be defined. However, no-
codazole may either bind directly to the transporter, or it may
modify the characteristics of the PM thus impairing the normal
function of the transporter.
The present studies do not exclude the possibility that
GLUT4 vesicles are transported along microtubules en route to
the PM. However, these studies clearly show that the insulin-
dependent recruitment of GLUT4 vesicles to the cell surface
can occur relatively unimpaired after depolymerization of the
microtubule network. Hence, our data suggest that it is un-
likely that microtubule-dependent transport is a major rate-
limiting step for the insulin-dependent delivery of GLUT4 to
the cell surface. Most importantly, these studies reveal an
effect of nocodazole, apparently unrelated to its microtubule-
depolymerizing effects, to interfere with the transport proper-
ties of facilitative glucose transporters. This effect may involve
many members of the glucose transport family, and so the use
of this drug to study the role of microtubules is probably best
confined to low doses where this nonspecific effect does not
occur.
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